IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by TD Asset Management Inc.

TD Asset Management Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 273,805 shares of the company’s stock after selling 20,907 shares during the period. TD Asset Management Inc. owned about 0.33% of IDEXX Laboratories worth $113,202,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $25,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories during the 4th quarter worth approximately $30,000. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories in the 4th quarter valued at approximately $31,000. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter worth $38,000. Finally, Crews Bank & Trust purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $41,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Trading Down 1.4 %

Shares of IDEXX Laboratories stock opened at $417.66 on Wednesday. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $437.36 and a 200-day simple moving average of $444.05. The stock has a market cap of $33.85 billion, a price-to-earnings ratio of 39.14, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent research reports. Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Leerink Partners started coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Morgan Stanley cut their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.